What is known and objective: With the advent of antiretroviral therapy and the resultant decrease in mortality among adults living with human immunodeficiency virus (HIV), there is now an increased incidence of obesity and obesity-related comorbidities in these patients. Bariatric surgery is becoming an increasingly common Results: Several case series and case reports have been published which demonstrate minimal risk of complications and maintenance of virologic suppression in the vast majority of patients. Bariatric surgery appears to be an effective mechanism for assistance in controlling obesity in patients infected with HIV; however, numerous factors may impact the safe and effective use of antiretroviral therapy.
Given the physiologic changes following bariatric surgery and its pharmacologic management perioperatively, many important considerations exist regarding the use of antiretroviral agents in this setting to ensure that efficacy is not compromised. A summary of considerations for select agents can be found in Table 1 . Few reports have been published which describe the pharmacotherapy of antiretrovirals following bariatric surgery and the safety of such procedures in the population of patients infected with HIV. The aim of this review article was to discuss pharmacologic considerations for specific antiretroviral agents in the setting of bariatric surgery. 
| ME THODS
Literature
| RE SULTS

| Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI)
| Abacavir
The site of absorption for abacavir is likely the proximal small intestine and is thought to be the duodenum. 6 Abacavir is rapidly and extensively absorbed. Therapeutic drug monitoring data are lacking for this agent.
An alternative formulation available for abacavir is the oral solution. 
| Emtricitabine
Emtricitabine displays rapid and extensive absorption; however, the site of absorption has not been studied. 8 A case report of a 38-year-old man with a recent diagnosis of HIV infection and a surgery history notable for Roux-en-Y gastric bypass was found to have a emtricitabine trough concentration of 57 ng/mL on a dose of 200 mg daily, similar to historical data according to the authors. An expected trough concentration for emtricitabine was referenced to be 47-112 ng/mL. 9 The patient's viral load was suppressed at the 6-month evaluation following initiation of antiretroviral therapy.
A case series of 10 patients with HIV infection who underwent sleeve gastrectomy included two patients receiving therapeutic drug monitoring for emtricitabine. Trough concentrations for these patients were 88 and 446 ng/mL, with each receiving daily doses of 200 mg. 10 Both patients maintained viral suppression postoperatively. It should be noted that therapeutic drug monitoring is not generally recommended for NRTIs given associated costs and the lack of clear correlation between plasma concentrations and clinical response. 11 Emtricitabine is also available as an oral solution.
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This formulation may be advantageous for patients with difficulty swallowing capsules following bariatric surgery.
| Lamivudine
The primary site of absorption for lamivudine is likely the proximal small intestine, namely the duodenum and jejunum. 6 Lamivudine is also rapidly and extensively absorbed, with a bioavailability of 86% in adults infected with HIV. 12 Limited data suggest normal serum concentrations of lamivudine in patients with HIV following Roux-en-Y 
| Tenofovir disoproxil fumarate
The site of absorption for tenofovir is likely the small intestines, although more specific data are lacking. 
| Zidovudine
The primary site of absorption for zidovudine is likely the small intestine, although more specific data are lacking for this agent.
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There are limited data to suggest that serum levels of zidovudine are not compromised in patients with HIV following Roux-en-Y gastric bypass. 
| Efavirenz
The primary site of absorption for efavirenz is the upper intestines. 20 The reference serum peak level for efavirenz is approximately 4000 ± 1100 ng/mL, and the reference serum trough level has been cited at 1700 ± 1000 ng/mL. 
| Etravirine
The site of absorption for etravirine is currently unknown. 24 The reference serum peak level for etravirine is 600 ng/mL, and the ref-
erence serum trough level is 300 ng/mL. 11 Etravirine is highly lipophilic, and its bioavailability is increased with food. Therefore, it is recommended to be administered following a meal. 
| Nevirapine
Nevirapine is extensively absorbed, with an estimated bioavailability of 90%. 27 It is absorbed throughout the intestines, but primarily in the jejunum, followed by the ileum. 28 The reference serum peak level is 5700 ng/mL, and the reference serum trough level is 4500 ± 1900 ng/mL. 11,21 Data regarding therapeutic drug monitoring of nevirapine following bariatric surgery are limited to one case of a patient with HIV infection who underwent sleeve gastrectomy.
The serum trough level of nevirapine taken 12 hours following drug administration was 2545 ng/mL. The patient was taking nevirapine at a dose of 200 mg by mouth twice daily as part of combination antiretroviral therapy and maintained viral suppression postoperatively. 10 An alternative formulation available for nevirapine is the oral suspension. 
| Rilpivirine
Information regarding the site of absorption for rilpivirine is lacking. Furthermore, the exact bioavailability of rilpivirine has not been elucidated. 29 It is well known that food increases the bioavailability of rilpivirine. Indeed, the exposure of rilpivirine is up to 40% lower when administered in a fasting state as compared to a fed state. 
| Protease inhibitors (PI)
| Atazanavir
The site of absorption for atazanavir is the intestine, although more specific data are unavailable. 32 The reference peak serum level of atazanavir is 5000 ± 2000 ng/mL, and the reference trough level is 2000 ± 1000 ng/mL. 
| Darunavir
The site of absorption for darunavir is likely the small intestine.
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The reference serum peak level for darunavir is 5200 ± 1600 ng/ mL, and the reference trough is 2200 ± 1100 ng/mL. All three patients achieved or maintained virologic suppression following surgery. For patient with difficulty swallowing tablets, darunavir is also available as an oral suspension. 
| Lopinavir
The site of absorption for lopinavir is the small intestines, and limited data suggest that the jejunum is the predominant site. 36,37 The reference serum peak level for lopinavir is 9600 ± 4400 ng/mL, and the reference trough is 5500 ± 4000 ng/mL, although a separate source suggests a reference trough as low as 700 ng/mL. 
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Despite this, the patient was able to maintain virologic suppression throughout her pregnancy.
14 Lopinavir/ritonavir is also available in an oral solution for patients with difficulty swallowing tablets. 
| Ritonavir
The site of absorption for ritonavir is currently unknown. 24 The absorption of 100 mg ritonavir tablet formulation is decreased approximately 20% when administered with food. 41 Given that ritonavir absorption is limited by solubility, a change in gastrointestinal pH may lead to alterations in absorption. 
| Raltegravir
Raltegravir is primarily absorbed in the ileum. 47 Bioavailability of raltegravir is significantly increased when administered with a highfat meal. 48 The reference serum peak level of raltegravir is 2050 ng/ mL, and the reference trough is 65 ng/mL. 11 Like dolutegravir and other integrase inhibitors, caution must be used with patients taking raltegravir and requiring supplementation with polyvalent cations.
Co-administration of raltegravir and calcium carbonate has resulted in a 55% decrease in raltegravir exposure. 
26
The authors of this report cited a recommended raltegravir concentration of >150 ng/mL at 12 hours from administration. A separate case of a patient with HIV infection who underwent sleeve gastrectomy was noted to have a raltegravir serum trough level of 83 ng/mL on a dose of 400 mg twice daily. 10 Both patients were able to maintain virologic suppression postoperatively. Raltegravir is also available as a chewable tablet formulation. Although this formulation has higher bioavailability than the film-coated tablet, it is not licensed for use in adults. 48 Unfortunately, there is a lack of clinical data with other integrase inhibitors in the setting of bariatric surgery.
| D ISCUSS I ON
There is a limited amount of literature evaluating the effect of bariat- consideration is also applicable for those undergoing sleeve gastrectomy given that 90% of the stomach is removed. 26 In addition, the ability to crush tablets must be considered as some patients may not be able to tolerate medications if swallowed whole or may not be amenable to taking liquid formulations due to volume and/ or taste. Potential drug-drug interactions with acid-suppressive medications and polyvalent cations should be taken into account when considering treatment options for these patients as there are certain antiretrovirals which will interact with these drugs and should not be co-administered due to decreased absorption resulting in decreased concentrations. 29, 33, 45, 46 Lastly, any adherence concerns should be taken into account in order to ensure patients will take all of the antiretroviral medications in addition to other medically necessary agents due to their comorbidities and bariatric surgery. 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; COBI, cobicistat; d4T, stavudine; ddI, didanosine; DM, diabetes mellitus; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; FPV, fosamprenavir; FTC, emtricitabine; GERD, gastroesophageal reflux disease; HLD, hyperlipidaemia; HTN, hypertension; LPV, lopinavir; NVP, nevirapine; PRE, preoperative; POST, postoperative; RAL, raltegravir; RPV, rilpivirine; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; UD, undetectable; ZDV, zidovudine.
The bold values signify the specific agent in the regimen that corresponds to the antiretroviral class.
a ART was being held due to nausea.
TA B L E 2 (Continued)
challenging to manage these HIV-infected individuals following gastric bypass surgeries. These patients should be followed closely prior to and postsurgery to ensure they achieve/maintain viral suppression. 
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